A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma
J. Pozniak, D. Pedri, E. Landeloos, Y. Van Herck, A. Antoranz, P. Karras, A. Nowosad, S. Makhzami, G. Bervoets, M. Dewaele, L. Vanwynsberghe, S. Cinque, S. Kint, K. Vandereyken, T. Voet, , J.-C. Marine
This study identifies a TCF4/BRD4-dependent regulatory network that drives cross-resistance to ICB and targeted therapy in melanoma by analyzing scRNA-seq data from a longitudinal cohort.
bioRxiv · Aug 11, 2022 · PreprintCancer Biology